An in vivo study indicates that upregulating USP48 can enhance the antitumor activity of PD-1 inhibitor [113], suggesting that USP48 activation pharmacologically could be a promising approach to enhance cancer cell sensitivity to pyroptosis and improve immunotherapy outcomes. The gene discussed is USP48; the disease is cancer.